Aerosolized liposomal Amphotericin B: A potential prophylaxis of invasive pulmonary aspergillosis in immunocompromised patients1. Issue 6 (10th July 2013)
- Record Type:
- Journal Article
- Title:
- Aerosolized liposomal Amphotericin B: A potential prophylaxis of invasive pulmonary aspergillosis in immunocompromised patients1. Issue 6 (10th July 2013)
- Main Title:
- Aerosolized liposomal Amphotericin B: A potential prophylaxis of invasive pulmonary aspergillosis in immunocompromised patients1
- Authors:
- Kamalaporn, Harutai
Leung, Kitty
Nagel, Mark
Kittanakom, Saranya
Calvieri, Battista
Reithmeier, Reinhart A.F.
Coates, Allan L. - Abstract:
- <abstract abstract-type="main" xml:lang="en"> <title>Summary</title> <sec id="ppul22856-sec-0001" sec-type="section"> <title>Background</title> <p>Aerosolized liposomal Amphotericin B may reduce the incidence of invasive pulmonary Aspergillosis in adults with chemotherapy‐induced prolonged neutropenia with less nephrotoxicity. The breath‐actuated AeroEclipse® BAN nebulizer is very efficient and minimizes environmental drug contamination since no aerosol is produced, unless the patient is inspiring through the device. Our aim is to develop an appropriate delivery system suitable for children that does not disrupt the liposomes due to the shear forces in nebulization.</p> </sec> <sec id="ppul22856-sec-0002" sec-type="section"> <title>Methods</title> <p>This is an in vitro experimental study in vitro. Six ml of 4 mg/ml liposomal Amphotericin B solution (AmBisome®; Astellas Pharma Inc., Markham, Ontario, CA) was nebulized with the breath‐actuated nebulizer (AeroEclipse®; Trudell Medical International, Canada) and captured by the glass liquid impinger. Sodium dodecyl sulfate was used as detergent to disrupt the liposomes in control samples. Gel filtration, electron microscopy, and high performance liquid chromatography (HPLC) were used to compare the size and shape of the liposomes, and amount of the drug before and after nebulization. The aerosol particle size was obtained by the laser diffraction.</p> </sec> <sec id="ppul22856-sec-0003" sec-type="section"><abstract abstract-type="main" xml:lang="en"> <title>Summary</title> <sec id="ppul22856-sec-0001" sec-type="section"> <title>Background</title> <p>Aerosolized liposomal Amphotericin B may reduce the incidence of invasive pulmonary Aspergillosis in adults with chemotherapy‐induced prolonged neutropenia with less nephrotoxicity. The breath‐actuated AeroEclipse® BAN nebulizer is very efficient and minimizes environmental drug contamination since no aerosol is produced, unless the patient is inspiring through the device. Our aim is to develop an appropriate delivery system suitable for children that does not disrupt the liposomes due to the shear forces in nebulization.</p> </sec> <sec id="ppul22856-sec-0002" sec-type="section"> <title>Methods</title> <p>This is an in vitro experimental study in vitro. Six ml of 4 mg/ml liposomal Amphotericin B solution (AmBisome®; Astellas Pharma Inc., Markham, Ontario, CA) was nebulized with the breath‐actuated nebulizer (AeroEclipse®; Trudell Medical International, Canada) and captured by the glass liquid impinger. Sodium dodecyl sulfate was used as detergent to disrupt the liposomes in control samples. Gel filtration, electron microscopy, and high performance liquid chromatography (HPLC) were used to compare the size and shape of the liposomes, and amount of the drug before and after nebulization. The aerosol particle size was obtained by the laser diffraction.</p> </sec> <sec id="ppul22856-sec-0003" sec-type="section"> <title>Results</title> <p>After nebulization, 97.5% of amphotericin B was captured by the liquid impinger and detected by HPLC. Gel filtration and electron microscopy demonstrated that the drug remained in its liposomal configuration after nebulization. The mass median diameter (MMD) was 3.7 μm and 66% of aerosol particles were less than 5 μm in diameter.</p> </sec> <sec id="ppul22856-sec-0004" sec-type="section"> <title>Conclusions</title> <p>We demonstrated that liposomal Amphotericin B can be nebulized successfully without disrupting the liposomes and minimize drug loss by using the breath‐actuated nebulizer. <bold>Pediatr Pulmonol. 2014; 49:574–580.</bold> © 2013 Wiley Periodicals, Inc.</p> </sec> </abstract> … (more)
- Is Part Of:
- Pediatric pulmonology. Volume 49:Issue 6(2014:Jun.)
- Journal:
- Pediatric pulmonology
- Issue:
- Volume 49:Issue 6(2014:Jun.)
- Issue Display:
- Volume 49, Issue 6 (2014)
- Year:
- 2014
- Volume:
- 49
- Issue:
- 6
- Issue Sort Value:
- 2014-0049-0006-0000
- Page Start:
- 574
- Page End:
- 580
- Publication Date:
- 2013-07-10
- Subjects:
- Pediatric respiratory diseases -- Periodicals
Pediatrics -- Periodicals
618.922 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1099-0496 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1002/ppul.22856 ↗
- Languages:
- English
- ISSNs:
- 8755-6863
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 6417.605800
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 3899.xml